ARIAD Pharma (ARIA) Announces Publication of Brigatinib Phase 1/2 Data; Median PFS Observed at 1+ Year
Tweet Send to a Friend
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced clinical data on its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, were published in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE